2022
Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States
Laditi F, Nie J, Jones T, Leapman MS. Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States. European Urology Focus 2022, 8: 910-912. PMID: 35778364, DOI: 10.1016/j.euf.2022.06.003.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingWhite patientsMagnetic resonance imaging (MRI) scansRisk stratification toolLarge observational studiesResonance imaging scansGene expression testStratification toolImaging scansCancer toolProstate cancerObservational studyPractice variationModifiable sourceResonance imagingGenetic testingPatientsRacial variationGenomic testingUS studiesLow useLess useExpression testReview
2021
NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing
Seiden B, Weng S, Sun N, Gordon D, Harris W, Barnett J, Myrie A, Jones T, Pak S, Fudl A, Shields J, McNeil B, Weiss J, Smith M, Esdaille A, Winer A. NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing. Urology 2021, 163: 81-89. PMID: 34688772, DOI: 10.1016/j.urology.2021.08.055.Peer-Reviewed Original ResearchConceptsNCCN riskIntermediate riskGenomic testingLower riskPre-biopsy prostate specific antigenNational Comprehensive Cancer Network guidelinesIntermediate-risk prostate cancerFavorable intermediate riskNCCN risk classificationPre-biopsy PSARisk classificationRisk prostate cancerUnfavorable intermediate riskProstate-specific antigenInitial risk classificationMedian ageBlack patientsNetwork guidelinesActive surveillanceProstate cancerHigher oddsSpecific antigenNonparametric statistical testingPatientsRiskEndourological management of a rare radiopaque ritonavir-composed urinary calculus
Laditi F, Khan A, Ghiraldi E, Jones T, Choksi A, Singh D. Endourological management of a rare radiopaque ritonavir-composed urinary calculus. Urology Case Reports 2021, 39: 101763. PMID: 34295648, PMCID: PMC8281602, DOI: 10.1016/j.eucr.2021.101763.Peer-Reviewed Original ResearchProtease inhibitorsCertain protease inhibitorsClinic complainingFlank painGross hematuriaSurgical removalEndourological managementUreteral stonesCT scanRitonavirUrinary stonesUrinary calculiUrinary stone componentsStone componentsInhibitorsFirst reportStonesHematuriaPainHIVAtazanavirPatientsNephrolithiasisComplaining